Overview

An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to evaluate the safety, tolerability and glucose-raising effects of RZ358 in patients with Congenital Hyperinsulinism (HI).
Phase:
Phase 2
Details
Lead Sponsor:
Rezolute